Treatment of viral hepatitis B in children

Bibliography

• World Health Organization. Department of Immunization, Vaccines and Biologicals. WHO vaccine-preventable disease: monitoring system. 2006 Global summary. Available from: www.who.int/vaccines-documents [Last accessed 1 Dec 2009]
   Google Scholar
• Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107
   PubMed Web of Science ®Google Scholar
• Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 2000;15:E3-6
   PubMed Web of Science ®Google Scholar
• Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996;38:S18-23
   PubMedGoogle Scholar
• Hepatitis B. World Health Organization Fact Sheet 204. World Health Organization, 2008. Avaiable from: http://www.who.int/mediacentre/factsheets/en/ [Last accessed 1 Dec 2009]
   Google Scholar
• Lok AS. Chronic hepatitis B. N Engl J Med 2002;346:1682-3
   PubMed Web of Science ®Google Scholar
• Chang M-H. Natural history of hepatitis B virus infection in children. J Gastroenterol Hepatol 2000;15:E16-19
   PubMed Web of Science ®Google Scholar
• Giacchino R, Zancan L, Vajro P, Hepatitis B virus infection in native versus immigrant or adopted children in Italy following the compulsory vaccination. Infection 2001;29:188-91
   PubMed Web of Science ®Google Scholar
• Lin K, Vickery J. Screening for hepatitis B virus infection in pregnant women: evidence for the US Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2009;150:874-6
   PubMed Web of Science ®Google Scholar
• Van Herck K, Van Damme P. Benefits of early hepatitis B immunization programs for newborns and infants. Pediatr Infect Dis 2008;27:861-9
   Google Scholar
• Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 summary of a workshop. Gastroenterology 2001;120:1828-53
   PubMed Web of Science ®Google Scholar
• Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136:699-712
   PubMed Web of Science ®Google Scholar
• Gigliotti AR, Fioredda F, Giacchino R. Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation. J Pediatr Hematol Oncol 2003;25:184-92
   PubMedGoogle Scholar
• Yuen M-F, Lai C-L. Natural history of chronic hepatitis B virus infection. J Gastroenterol Hepatol 2000;15:E20-4
   PubMed Web of Science ®Google Scholar
• Bortolotti F. Chronic viral hepatitis in childhood. Baillieres Clin Gastroenterol 1996;10:185-206
   PubMedGoogle Scholar
• Boxall EH, Sira J, Standish RA, Natural history of hepatitis B in perinatally infected carriers. Arch Dis Child Fetal Neonatal Ed 2004;89:F456-60
   PubMed Web of Science ®Google Scholar
• Bortolotti F, Jara P, Crivellaro C, Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol 1998;29:184-90
   PubMed Web of Science ®Google Scholar
• Bortolotti F, Wirth S, Crivellaro C, Long-term persistence of hepatitis B virus DNA in the serum of children with chronic hepatitis B after hepatitis B e antigen to antibody seroconversion. J Ped Gastroenterol Nutr 1996;22:270-4
   PubMedGoogle Scholar
• Bortolotti F, Guido M, Bartolacci S, Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006;43:556-62
   PubMed Web of Science ®Google Scholar
• Marx G, Martin SR, Chicoine JF, Alvarez F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J Infect Dis 2002;186:295-301
   PubMed Web of Science ®Google Scholar
• Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002;36:1408-15
   PubMed Web of Science ®Google Scholar
• Zacharakis G, Koskinas J, Kotsiou S, Natural history of chronic hepatitis B virus infection in children of different ethnic origins: a cohort study with up to 12 years' follow-up in northern Greece. J Pediatr Gastroenterol Nutr 2007;44:84-91
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39
   PubMed Web of Science ®Google Scholar
• Beasley RP, Hwang LY. Overview on the epidemiology of hepatocellular carcinoma. In: Hollinger FB, Lemon SM, Margolis H, editors, Viral hepatitis and liver disease. William & Wilkins, Baltimore, MD; 1991. p. 532-5
   Google Scholar
• Sumi H, Youkosuka O, Seki N, Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003;37:19-26
   PubMed Web of Science ®Google Scholar
• Hsu HY, Tsai HY, Wu TC, Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan. Liver Int 2008;28:1288-97
   PubMed Web of Science ®Google Scholar
• Chang MH, Hsu HY, Ni YH, Precore stop codon mutant in chronic hepatitis B virus infection in children: its relation to hepatitis B e seroconversion and maternal hepatitis B surface antigen. J Hepatol 1998;28:915-22
   PubMed Web of Science ®Google Scholar
• Godra A, Perez-Atayde AR, Jonas MM. Histopathologic features of chronic hepatitis B in children. Hepatology 2005;42:478-9A
   Google Scholar
• Giacchino R, Navone C, Facco F, HBV-DNA-related hepatocellular carcinoma occurring in childhood. Report of three cases. Dig Dis Sci 1991;36:1143-6
   PubMed Web of Science ®Google Scholar
• Pontisso P, Basso G, Perilongo G, Does hepatitis B virus play a role in primary liver cancer in children of Western countries? Cancer Detect Prev 1991;15:363-8
   PubMedGoogle Scholar
• Hsu HC, Wu MZ, Chang MH, Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. Report of 51 cases strongly associated with rapid development of liver cirrhosis. J Hepatol 1987;5:260-7
   PubMed Web of Science ®Google Scholar
• Ni YH, Chang MH, Huang LM, Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001;135:796-800
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:1-36
   PubMed Web of Science ®Google Scholar
• European association for the study of the liver. EASL Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42
   PubMed Web of Science ®Google Scholar
• Jara P, Bortolotti F. Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children. J Pediatr Gastroenterol Nutr 1999;29:163-70
   PubMed Web of Science ®Google Scholar
• Lai CL, Lok AS, Lin HJ, Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. Lancet 1987;2:877-80
   PubMed Web of Science ®Google Scholar
• Lai CL, Lin HJ, Lau JN, Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med 1991;78:155-63
   PubMedGoogle Scholar
• Lok AS, Lai CL, Wu PC, Treatment of chronic hepatitis B with interferon: experience in Asian patients. Semin Liver Dis 1989;9:249-53
   PubMed Web of Science ®Google Scholar
• Bortolotti F, Jara P, Barbera C, Long-term effect of alpha interferon in children with chronic hepatitis B. Gut 2000;46:715-18
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno M, Camps T, Jimenez J, Factors predictive of response to interferon therapy in children with chronic hepatitis B. J Hepatol 1995;22:540-4
   PubMedGoogle Scholar
• Ruiz Moreno M, Jimenez J, Porres JC, A controlled trial of recombinant interferon-alpha in Caucasian children with chronic hepatitis B. Digestion 1990;45:26-33
   PubMed Web of Science ®Google Scholar
• Sokal EM, Wirth S, Goyens P, Interferon alfa-2b therapy in children with chronic hepatitis B. Gut 1993;34:S87-90
   PubMedGoogle Scholar
• Sokal EM, Conjeevaram HS, Roberts EA, Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998;114:988-95
   PubMed Web of Science ®Google Scholar
• Utili R, Sagnelli E, Galanti B, Prolonged treatment of children with chronic hepatitis B with recombinant alpha 2a-interferon: a controlled, randomized study. Am J Gastroenterol 1991;86:327-30
   PubMed Web of Science ®Google Scholar
• Barbera C, Bortolotti F, Crivellaro C, Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. Hepatology 1994;20:287-90
   PubMed Web of Science ®Google Scholar
• Vajro P, Tedesco M, Fontanella A, Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection. Pediatr Infect Dis J 1996;15:223-31
   PubMed Web of Science ®Google Scholar
• Sira JK, Sleight E, Boxall E, Treatment of chronic hepatitis B carrier children in the UK [abstract 110]. Hepatology 1994;20:472
   Google Scholar
• Giacchino R, Main J, Timitilli A, Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B. Liver 1995;15:143-8
   PubMedGoogle Scholar
• Gürakan F, Koçak N, Ozen H, Yüce A. Comparison of standard and high dosage recombinant interferon alpha 2b for treatment of children with chronic hepatitis B infection. Pediatr Infect Dis J 2000;19:52-6
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno M, Rua MJ, Molina J, Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis B. Hepatology 1991;13:1035-9
   PubMed Web of Science ®Google Scholar
• Gregorio GV, Jara P, Hierro L, Lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B: a multicentre controlled trial. Hepatology 1996;23:700-7
   PubMed Web of Science ®Google Scholar
• Torre D, Tambini R. Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis. Clin Infect Dis 1996;23:131-7
   PubMed Web of Science ®Google Scholar
• Verucchi G, Attard L, Mori F, Interferon alpha is efficient in the treatment of children with chronic hepatitis B [abstract]. Hepatology 1994;20:301A
   Google Scholar
• Iorio R, Pensati P, Botta S, Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J 1997;16:984-90
   PubMed Web of Science ®Google Scholar
• Lin ZQ, Fang F, Guo ZF, Chen Q. Effect of interferonalpha treatment in children with hepatitis B e antigenpositive chronic hepatitis B virus infection: a metaanalysis of follow-up for six months to two years. Zhonghua Er Ke Za Zhi 2007;45:592-8
   PubMedGoogle Scholar
• Kobak GE, MacKenzie T, Sokol RJ, Narkewicz MR. Interferon treatment for chronic hepatitis B: enhanced response in children 5 years old or younger. J Pediatr 2004;145:340-5
   PubMed Web of Science ®Google Scholar
• Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int 2005;25:1097-107
   PubMed Web of Science ®Google Scholar
• Zhao H, Kurbanov F, Wan MB, Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis 2007;44:541-8
   PubMed Web of Science ®Google Scholar
• Vajro P, Migliaro F, Fontanella A, Orso G. Interferon: a meta-analysis of published studies in pediatric chronic hepatitis B. Acta Gastroenterol Belg 1998;61:219-23
   PubMed Web of Science ®Google Scholar
• Iorio R, Giannattasio A, Cirillo F, Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin Infect Dis 2007;45:943-9
   PubMed Web of Science ®Google Scholar
• Diem HVT, Bourgois A, Bontems P, Chronic hepatitis B infection: long term comparison of children receiving interferon-alpha and untreated controls. J Pediatr Gastroenterol Nutr 2005;40:141-5
   PubMed Web of Science ®Google Scholar
• Ertem D, Acar Y, Kotiloğlu Karaa E, Pehlivanoğlu E. High-dose interferon results in high HBsAg seroclearance in children with chronic hepatitis B infection. Turk J Pediatr 2003;45:123-8
   PubMedGoogle Scholar
• Ozen H, Kocak N, Yuce A, Gurakan F. Retreatment with higher dose interferon alpha in children with chronic hepatitis B infection. Pediatr Infect Dis J 1999;18:694-7
   PubMed Web of Science ®Google Scholar
• Mellerup MT, Krogsgaard K, Mathurin P, Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. Cochrane Database Syst Rev 2009;4:CD000345
   Google Scholar
• Boxall EH, Sira J, Ballard AL, Long-term follow-up of hepatitis B carrier children treated with interferon and prednisolone. J Med Virol 2006;78:888-95
   PubMed Web of Science ®Google Scholar
• Pawloska M, Halota W. Virological response during treatment of chronic hepatitis B with pegylated interferon alfa-2a in children [abstract M1922]. Gastroenterology 2008:A811
   Google Scholar
• Michaud AP, Bauman NM, Burke DK, Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope 2004;114:1231-6
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Schiff ER, Mitchell M, Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999;30:1082-7
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Papatheodoridis GV, Dimou E, Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-51
   PubMed Web of Science ®Google Scholar
• Liaw YF, Chien RN, Yeh CT, Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-72
   PubMed Web of Science ®Google Scholar
• Sokal EM, Roberts EA, Mieli-Vergani G, A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob Agents Chemother 2000;44:590-7
   PubMed Web of Science ®Google Scholar
• Jonas MM, Mizerski J, Badia IB, Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13
   PubMed Web of Science ®Google Scholar
• Sokal EM, Kelly DA, Mizerski J, Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006;43:225-32
   PubMed Web of Science ®Google Scholar
• Jonas MM, Little NR, Gardner SD; International Pediatric Lamivudine Investigator Group. Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety. J Viral Hepat 2008;15:20-7
   PubMed Web of Science ®Google Scholar
• Liberek A, Szaflarska-Popławska A, Korzon M, Lamivudine therapy for children with chronic hepatitis B. World J Gastroenterol 2006;12:2412-16
   PubMed Web of Science ®Google Scholar
• Choe BH, Lee JH, Jang YC, Long-term therapeutic efficacy of lamivudine compared with interferon-alpha in children with chronic hepatitis B: the younger the better. J Pediatr Gastroenterol Nutr 2007;44:92-8
   PubMedGoogle Scholar
• Koh H, Baek SY, Chung KS. Lamivudine therapy for korean children with chronic hepatitis B. Yonsei Med J 2007;48:927-33
   PubMedGoogle Scholar
• Ozgenç F, Arikan C, Sertoz RY, Effect of long-term lamivudine in chronic hepatitis B virus-infected children. Antivir Ther 2004;9:729-32
   PubMedGoogle Scholar
• Hartman C, Berkowitz D, Eshach-Adiv O, Long-term lamivudine therapy for chronic hepatitis B infection in children unresponsive to interferon. J Pediatr Gastroenterol Nutr 2006;43:494-8
   PubMedGoogle Scholar
• Selimoglu MA, Aydogdu S, Unal F, Alpha interferon and lamivudine combination therapy for chronic hepatitis B in children. Pediatr Int 2002;44:404-8
   PubMed Web of Science ®Google Scholar
• Dikici B, Bosnak M, Kara IH, Lamivudine and interferon-alpha combination treatment of childhood patients with chronic hepatitis B infection. Pediatr Infect Dis J 2001;20:988-92
   PubMedGoogle Scholar
• Dikici B, Bosnak M, Bosnak V, Comparison of treatments of chronic hepatitis B in children with lamivudine and alpha-interferon combination and alpha-interferon alone. Pediatr Int 2002;44:517-21
   PubMed Web of Science ®Google Scholar
• Elkabes B, Suoglu OD, Sokucu S, Saner G. Lamivudine and alpha interferon combination treatment versus alpha interferon treatment in children with chronic hepatitis B infection. J Hepatol 2001:161
   PubMedGoogle Scholar
• Sokucu S, Gokçe S, Suoglu OD, Comparison of interferon monotherapy with interferon-lamivudine combination treatment in children with chronic hepatitis B. Indian J Gastroenterol 2006;25:136-9
   PubMedGoogle Scholar
• Koçak N, Özen H, Saltik IN, Comparison of lamivudine (LMV) with LMV + interferon (IFN)-alpha treatments in children with chronic hepatitis B (CHB) who were nonresponders to previous IFN-alpha treatment. J Ped Gastroenterol Nutr 2000;31:1063A
   Google Scholar
• Kutlu T, çullu F, Erkan T, Tümay GT. Lamivudine and alpha interferon combination therapy for chronic hepatitis B infection in children: a preliminary trial. J Pediatr Gastroenterol Nutr 2000;31:443
   Google Scholar
• Akman SA, Okcu SC, Halicioğlu O, Therapeutic efficacy of sequential and simultaneous treatments with interferon-alpha and lamivudine in children with chronic hepatitis B. Pediatr Int 2007;49:848-52
   PubMedGoogle Scholar
• Hartman C, Berkowitz D, Shouval D, Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon. Pediatr Infect Dis J 2003;22:224-9
   PubMedGoogle Scholar
• Saltik Temizel IN, Kocak N, Demir H, Two years results of lamivudine (LMV) alone and LMV plus interferon (IFN) treatment in children with chronic hepatitis B (CHB) who were non-responders to IFN. J Hepatol 2003;38:168-9
   Google Scholar
• Arif B, Selim I, Ferhan K, Ismail G. Efficacy of interferon alpha-2b and lamivudine therapy for chronic hepatitis B in children. Chin Med J (Engl) 2003;116:593-6
   PubMedGoogle Scholar
• D'Antiga L, Aw M, Atkins M, Combined lamivudine/interferon-alpha treatment in ‘immunotolerant’ children perinatally infected with hepatitis B: a pilot study. J Pediatr 2006;148:228-33
   PubMed Web of Science ®Google Scholar
• Perrillo R, Schiff E, Yoshida E, Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-34
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG, Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16
   PubMed Web of Science ®Google Scholar
• Jonas MM, Kelly D, Pollack H, Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to < 18 years) with chronic hepatitis B. Hepatology 2008;47:1863-71
   PubMed Web of Science ®Google Scholar
• Open-label study of pharmacokinetics and safety of dose of adefovir dipivoxil in children and adolescents with HBV. NCT00645294. Available from: http://clinicaltrials.gov/ct2/show/NCT00645294 [Last accessed 1 Dec 2009]
   Google Scholar
• Safety and efficacy of adefovir dipivoxil in children and adolescents with chronic hepatitis B. NCT00095121. Available from: http://www.clinicaltrial.gov/ct2/show/NCT00095121 [Last accessed 1 Dec 2009]
   Google Scholar
• Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004;2:266-72
   PubMed Web of Science ®Google Scholar
• van Bommel F, Wunsche T, Mauss S, Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-5
   PubMed Web of Science ®Google Scholar
• Marcellini P, Heathcote EJ, Buti M, Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55
   PubMedGoogle Scholar
• Evaluation of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B infection. NCT00734162. Available from: http://www.clinicaltrial.gov/ct2/show/NCT000734162 [Last accessed 1 Dec 2009]
   Google Scholar
• Lai CL, Gane E, Chao-Wei H, Two-year results from the Globe Trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine. Hepatology 2006;44:222A
   Google Scholar
• Di Bisceglie AM, Lai CL, Gane E, Telbivudine Globe Trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology 2006;44:230-1A
   Google Scholar
• Pharmacokinetics and safety of single-dose telbivudine in children and adolescents with chronic hepatitis B. NCT00907894. Available from: http://clinicaltrials.gov/ct2/show/NCT00907894 [Last accessed 1 Dec 2009]
   Google Scholar
• Chang TT, Gish RG, de Man R, A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10
   PubMed Web of Science ®Google Scholar
• Sherman M, Yurdaydin C, Sollano J, Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-49
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis 2007;11:965-91
   PubMedGoogle Scholar
• Cheng AL, Hsiung CA, Su IJ, Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003;37:1320-8
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan PK, Zhong S, Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307
   PubMed Web of Science ®Google Scholar
• Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-20
   PubMed Web of Science ®Google Scholar
• Faraci M, Cappelli B, Lanino E, Hepatitis B reactivation in allogeneic hemopoietic stem cell transplantation setting: a pediatric experience. Pediatr Transplant 2009;13:923-6
   PubMedGoogle Scholar
• Katz LH, Fraser A, Gafter-Gvili A, Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008;15:89-102
   PubMed Web of Science ®Google Scholar
• Andreone P, Fiorino S, Cursaro C, Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial. Antiviral Res 2001;49:75-81
   PubMed Web of Science ®Google Scholar
• Gerner P, Posselt HG, Krahl A, Vitamin E treatment for children with chronic hepatitis B: a randomized placebo controlled trial. World J Gastroenterol 2008;14:7208-13
   PubMedGoogle Scholar
• Fattovich G, Cadrobbi P, Crivellaro C, Virological changes in chronic hepatitis type B treated with levamisole. Digestion 1982;25:131-7
   PubMedGoogle Scholar
• Krastev Z, Jelev D, Antonov K, Chronic HBV infection. Immunomodulation with levamisole in viremic HBeAg positive or anti-HBe positive patients – a pilot study. Hepatogastroenterology 1999;46:3184-8
   PubMedGoogle Scholar
• Ruiz-Moreno M, García R, Rua MJ, Levamisole and interferon in children with chronic hepatitis B. Hepatology 1993;18:264-9
   PubMed Web of Science ®Google Scholar
• Karaoglan M, Demirci F, Coskun Y, Immunomodulation therapy in children with chronic hepatitis B. J Natl Med Assoc 2006;98:143-7
   PubMedGoogle Scholar
• Senturk H, Tabak F, Ozaras R, Efficacy of pre-S-containing HBV vaccine combined with lamivudine in the treatment of chronic HBV infection. Dig Dis Sci 2009;54:2026-30
   PubMedGoogle Scholar